Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO

As part of CEO Paul Hudson’s mission to revamp the company’s strategy around oncology and immunology R&D, Sanofi unwrapped plans in February to hive off its legacy API business. But Sanofi wants to maintain its EU heritage for the new company, and now has a name and new leader to move the spinoff ahead.